NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as CUBIST PHARMS LLC. It is marketed under 1 brand name, including SIVEXTRO. Available in 2 different strengths, such as 200MG/VIAL, 200MG, and administered through 2 routes including POWDER;INTRAVENOUS, TABLET;ORAL.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"67730","ingredient":"TEDIZOLID PHOSPHATE","trade_name":"SIVEXTRO","family_id":"c890677075a74a3cbe6b","publication_number":"US8420676B2","cleaned_patent_number":"8420676","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-02-23","publication_date":"2013-04-16","legal_status":"Expired"} | US8420676B2 Molecular Formulation | 16 Apr, 2013 | Expired | 23 Feb, 2028 | |
| {"application_id":"67763","ingredient":"TEDIZOLID PHOSPHATE","trade_name":"SIVEXTRO","family_id":"c890677075a74a3cbe6b","publication_number":"US7816379B2","cleaned_patent_number":"7816379","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-06-20","publication_date":"2010-10-19","legal_status":"Granted"} | US7816379B2 Molecular Formulation | 19 Oct, 2010 | Granted | 20 Jun, 2028 | |
| {"application_id":"67724","ingredient":"TEDIZOLID PHOSPHATE","trade_name":"SIVEXTRO","family_id":"b41ade42a7cc46d2a063","publication_number":"US10442829B2","cleaned_patent_number":"10442829","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-02-03","publication_date":"2019-10-15","legal_status":"Granted"} | US10442829B2 Molecular | 15 Oct, 2019 | Granted | 03 Feb, 2030 | |
| {"application_id":"67723","ingredient":"TEDIZOLID PHOSPHATE","trade_name":"SIVEXTRO","family_id":"b41ade42a7cc46d2a063","publication_number":"US10065947B2","cleaned_patent_number":"10065947","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-02-03","publication_date":"2018-09-04","legal_status":"Patented case"} | US10065947B2 Formulation | 04 Sep, 2018 | Patented case | 03 Feb, 2030 | |
| {"application_id":"67721","ingredient":"TEDIZOLID PHOSPHATE","trade_name":"SIVEXTRO","family_id":"b41ade42a7cc46d2a063","publication_number":"US9624250B2","cleaned_patent_number":"9624250","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-02-03","publication_date":"2017-04-18","legal_status":"Granted"} | US9624250B2 Molecular Formulation | 18 Apr, 2017 | Granted | 03 Feb, 2030 | |
| {"application_id":"67722","ingredient":"TEDIZOLID PHOSPHATE","trade_name":"SIVEXTRO","family_id":"b41ade42a7cc46d2a063","publication_number":"US9988406B2","cleaned_patent_number":"9988406","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-02-03","publication_date":"2018-06-05","legal_status":"Granted"} | US9988406B2 Formulation | 05 Jun, 2018 | Granted | 03 Feb, 2030 | |
| {"application_id":"67687","ingredient":"TEDIZOLID PHOSPHATE","trade_name":"SIVEXTRO","family_id":"b41ade42a7cc46d2a063","publication_number":"US8426389B2","cleaned_patent_number":"8426389","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-12-31","publication_date":"2013-04-23","legal_status":"Granted"} | US8426389B2 Molecular Formulation | 23 Apr, 2013 | Granted | 31 Dec, 2030 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Tedizolid Phosphate
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.